Bial Reports Topline Results From ACTIVATE Phase 2b Study in GBA‑Associated Parkinson’s
PORTO, Portugal–(BUSINESS WIRE)–Bial, an innovation-driven biopharmaceutical company focused on neurosciences and rare diseases, announced today that the Phase…